Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Discover 3 strategies outperforming the Dividend Aristocrat Index with higher yields and superior CAGR. Start 2025 with ...

As market uncertainty continues to grow amid ongoing tariff discussions, many market participants may begin increasing their ...

B&D White Capital Company LLC raised its stake in Johnson & Johnson by 82.7% in the fourth quarter, purchasing 3,350 ...

The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Check out the list of dividend ...

We recently published a list of 7 Cheap Global Stocks to Buy Right Now. In this article, we are going to take a look at where ...

Trash isn’t just trash anymore; it’s a billion-dollar opportunity. With industries going green and consumers demanding ...

Delving into the details, we found 50% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we ...

We recently compiled a list of the Top 10 Dividend Stocks To Buy According To Hedge Funds. In this article, we are going to ...

In the last few weeks, we’ve talked a lot about “hated” dividends set to soar as mainstream investors get it wrong on Trump 2 ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

For investors seeking a balance of risk management and income, a mix of low-volatility, high-dividend stocks can be a smart ...